Journal of Virology & Antiviral ResearchISSN: 2324-8955

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article, J Virol Antivir Res Vol: 3 Issue: 4

Twice Daily Dosing of Telaprevir for Treatment-Naive and Treatment-Experienced Patients with Hepatitis C Infection

David M You1, Douglas Hunt2, Michael W Fried3, David R Nelson4, Andrea Scherschel2, Bryan Still2 and Paul J Pockros2,5*
1Department of Gastroenterology, Naval Medical Center San Diego, USA
2Division of Gastroenterology/Hepatology, Scripps Clinic, La Jolla, CA, USA
3Division of Gastroenterology, University of North Carolina, USA
4Division of Gastroenterology/Hepatology, University of Florida, USA
5Scripps Translational Science Institute, La Jolla, CA, USA
Corresponding author : Paul J Pockros
Scripps Clinic, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 1 (858) 554-8879; Fax: 1 (858) 541-1200
Received: June 16, 2014 Accepted: December 10, 2014 Published: December 17, 2014
Citation: You DM, Hunt D, Fried MW, Nelson DR, Scherschel A, et al. (2014) Twice Daily Dosing of Telaprevir for Treatment-Naive and Treatment-Experienced Patients with Hepatitis C Infection. J Virol Antivir Res 3:4. doi:10.4172/2324-8955.1000133


Background & Aims: Twice daily dosing of telaprevir in combination with peg interferon/ribavirin has not been extensively studied in treatment-naïve and treatment-experienced genotype 1 HCV patients, including a “real-world” setting. The purpose of this study was to assess the effectiveness and safety of telaprevir dosed at 1125 mg Q12 hr in treatment-naïve and treatment-experienced patients with genotype 1 chronic HCV infection in both a clinical study and “real-world” setting. Methods: A total of 163 subjects were evaluated in this study, including 103 treatment-naïve and treatment-experienced HCV genotype 1 patients who were treated prospectively with telaprevir 1125 mg Q12 hr along with peg interferon/ribavirin. In addition, we reviewed “real-world” data from a large multicenter longitudinal database (HCV-TARGET) of 60 treatment-naïve and treatment-experienced patients who received telaprevir dosed twice daily with peg interferon/ribavirin. Results: In a clinical study setting, the SVR 12 was 73% in treatment-naïve/relapsers and 41% in prior treatment-failures while in a “real-world” setting, the SVR 12 was 64% and 33%, respectively. Overall, treatment discontinuation due to adverse events occurred in 21% of treatment-naïve/relapsers and 53% of prior treatment-failures.

Conclusions: In our study, response rates to telaprevir taken twice daily appear to be similar to published sustained virologic rates for telaprevir taken every 8 hours for treatment of genotype 1 HCV infection for both treatment-naïve and treatment-experienced patients, although a lower SVR12 was seen in a “real-world” setting.

Keywords: Chronic hepatitis C; Treatment-naive; Treatment-experienced; BID dosing; Telaprevir

international publisher, scitechnol, subscription journals, subscription, international, publisher, science

Track Your Manuscript

Awards Nomination

Recommended Conferences

Media Partners

open access